We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Fujirebio Europe Launches RoboBlot Instrument for Fully Automated Processing of INNO-LIA Score Assays

By LabMedica International staff writers
Posted on 19 Jan 2022

Fujirebio Europe (Gent, Belgium) has announced today the commercial launch of the RoboBlot instrument, a closed system for the automated processing of the widely used INNO-LIA Score assays. More...

The system’s pre-programmed test protocols provide start-to-finish automation of strip-based INNO-LIA Score assays, from sample addition, over strip processing, image capture, to result interpretation and where applicable laboratory information system (LIS) communication.

RoboBlot extends the range of automated solutions already offered by Fujirebio Europe for the INNO-LIA Score assay portfolio. It offers high-throughput testing, full automation with pipetting up to 50 samples and integrated camera for scanning and interpretation with Fujirebio LiRAS software, providing complete traceability with minimal hands-on time. It offers a customized fit with individual laboratory needs. Other automated solution for this portfolio is the TENDIGO.

“High throughput testing and more automation are an increasingly pressing need for laboratories. The typical drawbacks of manual testing, such as long hands-on time, inconsistent assay handling and issues with traceability, will become part of the past,” said Christiaan De Wilde, CEO at Fujirebio Europe. “The RoboBlot instrument will radically improve the laboratory workflow for our customers, from tedious manual or semi-automated work into fully automated testing.”

Related Links:
Fujirebio Europe 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.